Economic Evaluation in Genomic Medicine
- 1st Edition - March 20, 2015
- Latest edition
- Authors: Vasilios Fragoulakis, Christina Mitropoulou, Marc Williams, George P. Patrinos
- Language: English
Economic Evaluation in Genomic Medicine introduces health economics and economic evaluation to genomic clinicians and researchers, while also introducing the topic to health ec… Read more
Description
Description
Economic Evaluation in Genomic Medicine introduces health economics and economic evaluation to genomic clinicians and researchers, while also introducing the topic to health economists.
Each chapter includes an executive summary, questions, and case studies, along with supplementary online materials, including process guides, maps, flow charts, diagrams, and economic evaluation spreadsheets to enhance the learning process.
The text can easily be used as course material for related graduate and undergraduate courses, providing a succinct overview of the existing, state-of-the-art application of economic evaluation to genomic healthcare and precision medicine.
Key features
Key features
- Interrelates economic evaluation and genomic medicine
- Instructs healthcare professionals and bioscientists about economic evaluation in genomic medicine
- Teaches health economists about application of economic evaluation in genomic medicine
- Introduces health economics and economic evaluation to clinicians and researchers involved in genomics
- Includes process guides, maps, flow charts and diagrams
Readership
Readership
Table of contents
Table of contents
- Preface
- Chapter 1. Economic Evaluation in Health Care: Evidence-Based Medicine and Evidence-Based Health Economics
- The Scope of Economic Evaluation of Health Services: The Science of Economics
- Evidence-Based Medicine and Evidence-Based Health Economics
- The Necessity of Drafting Economic Evaluations
- References
- Chapter 2. Genomic Medicine Today: An Introduction for Health Economists
- Introduction
- Pharmacogenomics and Genomic Medicine
- Applications of Pharmacogenomics
- Facing the Current Challenges of Genomic Medicine
- Education of Health Professionals
- Demonstration of Clinical Utility
- Health Care Costs
- Insurance and Privacy Issues
- Conclusions and Future Perspectives
- References
- Chapter 3. Economic Evaluation and Genomic Medicine: What Can They Learn from Each Other?
- Introduction
- Genomics in Health Economics
- Triangulating Genomics with Health Technology Assessment and Health Economics
- Economic Evaluation in the Postgenomic Era
- References
- Chapter 4. Introduction to the Technical Issues of Economic Evaluation
- Introduction
- Unique Aspects and Differentiation of CEA from Alternative Approaches
- An Appropriate Measure for CEA
- CEA Decision Criteria
- The Concept of Extended Dominance
- Selection of Alternative Options During Economic Evaluation
- Valuing the Quality of Life–Cost–Utility Analysis
- A Conceptual Approach to QALY
- Assessing the Quality of an Economic Analysis
- Conclusions
- References
- Chapter 5. Advanced Methodological Aspects in the Economic Evaluation
- Introduction
- Model Types
- The Size of the ICER or the λ
- Estimates of Effectiveness
- Study Perspective and Cost Determination
- The Discount Rate
- Sensitivity Analysis
- The Value of Information and Bayesian Analysis
- Conclusions
- References
- Chapter 6. Economic Evaluation in the Genomic Era: Some Examples from the Field
- Introduction
- Using Pharmacogenomics to Prevent Adverse Events
- Balancing Adverse Events and Efficacy
- The Disease Makes a Difference
- Perspectives on Perspective
- Defining Performance Characteristics
- Cost-Effectiveness Analysis in Genomic Medicine and the Developing World
- Conclusions
- References
- Chapter 7. Special Requirements for Economic Evaluation and Health Technology Assessment in Genomic Medicine
- Introduction
- Analysis Costs
- Analysis Method
- Outcome of Analysis
- Analysis Effectiveness
- Conclusions
- References
- Chapter 8. A New Methodological Approach for Cost-Effectiveness Analysis in Genomic Medicine
- Introduction
- New Methodological Framework of the Decision-Making Process in Genomic Medicine
- Relaxation of Fixed λ
- A Simple Indicative Example
- An Application of the New Model in Genomic Medicine
- Implications
- Conclusions
- References
- Chapter 9. Conclusions and Future Perspectives
- Introduction
- Conclusions
- References
- Index
Review quotes
Review quotes
"...provides a useful introduction to health economics for non-specialists interested in how it can be applied to genomics, and the relevance of this on policy, reimbursement, and availability of diagnostics and related therapies."—European Journal of Human Genetics
Product details
Product details
- Edition: 1
- Latest edition
- Published: March 20, 2015
- Language: English
About the authors
About the authors
VF
Vasilios Fragoulakis
CM
Christina Mitropoulou
MW
Marc Williams
GP
George P. Patrinos
George P. Patrinos is a Professor of Pharmacogenomics and Pharmaceutical Biotechnology in the University of Patras (Greece), Department of Pharmacy, and Head of Division of Pharmacology and Biosciences of the same department and holds adjunct Full Professorships at Erasmus MC, Faculty of Medicine, and Health Sciences, Rotterdam (the Netherlands), and the United Arab Emirates University, College of Medicine, Department of Genetics and Genomics, Al-Ain (UAE). Also, from 2018 until the end of 2024, he was Chair of the Global Genomic Medicine Collaborative (G2MC). He served 12.5 years as a full member and Greece’s National representative in the CHMP Pharmacogenomics Working Party of the European Medicines Agency (EMA). George has more than 340 publications in peer-reviewed scientific journals, some of them in leading scientific journals, such as The Lancet, Nature Genetics, Nature Reviews Genetic, Nucleic Acids Research, Genes & Development. He has also coauthored and coedited more than 15 textbooks, among which the renowned textbook Molecular Diagnostics, published by Academic Press, now in its 3rd edition, while he is the editor of Translational and Applied Genomics book series, published by Elsevier. Furthermore, he serves as the Editor-In-Chief of the prestigious Pharmacogenomics Journal (TPJ), published by Nature Publishing Group, Associate Editor, and member of the editorial board of several scientific journals, and advisory and evaluation committees. Apart from that, George is the main coorganizer of the Golden Helix Conferences, an international meeting series on Pharmacogenomics and Genomic Medicine with more than 50 conferences organized in more than 25 countries worldwide.